DOCSLIB.ORG

List of Section 13F Securities, 2Nd Quarter 1998

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Section 13F Securities, 2Nd Quarter 1998 USER INFORMATION SHEET General This list of "Section 13 (f) securities" as defined by Rule 13f-1 (c) [17 CFR 240.13f-1 (c)] is made available to the public pursuant to Section 13(f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. 1't is made available for use in the preparation of reports filed with the Securities and Exchange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-11 under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of June 15, 1998, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending June 30, 1998. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder. Features (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled "STATUS." The word "ADDED" in the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word "DELETED" in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) List of Options: An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSIP number immediately below the name of the security having the option. A manager reporting holdings of options on its Form 13F should use the CUSIP number of each option as to which holdings are reported. CUSIP descriptions and numerical identification data (copyright 1969 through 1996, American Bankers Association) are used with permission. All rights reserved. RUN DATE:06/23/98 %* LIST OF SECTION 13F SECURITIES ** PAGE 1 RUN TIME:16:46 IUMOOl CUSIP NO. ISSUER NAME ISSUER DESCRIPTION STATUS 849233 10 7 ICOS VISION SYS CORP N V ORD B5628B 10 4 X LERNOUT 8 HAUSPIE SPEECH PRODS COM B5628B 90 4 LERNOUT 8 HAUSPIE SPEECH PRODS CALL B5628B 95 4 LERNOUT 8 HAUSPIE SPEECH PRODS PUT D0882P 10 3 BENCKISER N V CL B G0070K 10 3 * ACE LTD 0 RD G0070K 90 3 ACE LTD CALL Glt070K 95 3 ACE LTD PUT 602702 10 1 AMERICAN CRAFT BREWING INTL COM GO2702 11 9 AMERICAN CRAFT BREWING INTL WT EXP 091101 GO2995 10 1 AMERICAN SAFETY INS GROUP LTD ORD G0352M 10 8 AMWAY ASIA PACIFIC LTD COM 60352M 90 8 AMWAY ASIA PACIFIC LTD CALL G0352M 95 8 AMWAY ASIA PACIFIC LTD PUT GO3910 10 9 ANNUITY AND LIFE RE HLDGS 0 RD ADDED 604074 10 3 APEX SILVER MINES LTD ORD 604450 10 5 ARAMEX INTL LTD ORD 605345 10 6 ASIA PACIFIC RES INTL HLDG LTD CL A G0535E 10 6 ASIA PACIFIC WIRE 8 CABLE CORP ORD G1368B 10 2 BRILLIANCE CHINA AUTO HLDG LTD COM 61863~10 3 CAPITAL MEDIA GROUP LTD COM DELETED G1981E 10 3 CAYMAN UArEK CO LTD ORD 620045 10 3 CENTRAL EUROPEAN MEDIA ENTRPRS CL A GZ107X 10 8 CHINA TIRE HLDGS LTD COM 621082 10 5 CHINA YUCHAl INTL LTD COM GZlOYA 10 6 CHINA ENERGY RES COKP ORD G22984 10 1 * COMCAST UK CABLE PARTNERS LTD CL A 622984 90 1 COMCAST UK CABLE PARTNERS LTD CALL 622984 95 1 COMCAST UK CABLE PARTNERS LTD PUT C23257 10 1 COMMODORE HLDGS LTD ORD 623257 11 9 COMMODORE HLDGS LTD WT EXP 071501 G2519Y 10 8 CREDICORP LTD COM GZ829S 10 6 DRANSFIELD CHINA PAPER CORP ORD 626471 10 3 DSG INTL LTU ORD 624526 10 3 EK CHOK CHINA MOTORCYCLE CO COM 631215 10 9 ESG RE LTD ORD 632030 10 1 EURO TECH HOLDINGS CO LTD ORD 632030 11 9 EURO TECH HOLDINGS CO LTD WT EX 000003 63242A 10 2 * EXEL LTD ORD G3242A 90 2 EXEL LTD CALL G3242A 95 2 EXEL LTD PUT 03287M 10 2 EZCONY INTERAMERICA INC ORD 634874 10 0 FIRST SOUTH AFRICA CORP LTD ORD 634874 11 8 FIRST SOUTH AFRICA CORP LTD WT A EX 012401 634874 12 6 FIRST SOUTH AFRICA CORP LTD WT B EX 012401 634374 13 4 FIRST SOUTH AFRICA CORP LTD UNIT EX 012301 (36738 10 5 * FRESH DEL MONTE PRODUCE INC ORD 636738 90 5 FRESH DEL MONTE PRODUCE INC CALL 636738 95 5 FRESH DEL MONTE PRODUCE INC PUT RUN DATE:06/23/98 ** LIST OF SECTION 13F SECURITIES %* PAGE 2 RUN TIME:16:46 IVMOOl CUSIP NO. ISSUER NAME ISSUER DESCRIPTION STATUS G3788V 10 6 * GEMSTAR INTL GROUP LTD ORD G3788V 90 6 GEMSTAR INTL GROUP LTD CALL G3788V 95 6 GEMSTAR INTL GROUP LTD PUT G3930H 10 4 * GLOBALSTAR IELECOMMUNICTNS LTD COM G3930H 90 4 GLOBALSTAR 1-ELECOMMUNICTNS LTD CALL G3930H 95 4 GLOBALSTAR 1'ELECOMMUNICTNS LTD PUT 639320 10 9 GLOBAL-TECH APPLIANCES INC ORD ADDED G4388N 10 6 * HELEN OF TROY CORP LTD COM G4388N 90 6 HELEN OF TROY CORP LTD CALL G4388N 95 6 HELEN OF TROY CORP LTD PUT G4481U 10 6 HIGHWAY HLDGS LTD ORD G4481U 11 4 HIGHWAY HLDGS LTD WT EXP 000001 G4802P 10 9 INTERACTIVE ENTERTAINMENT LTD COM G4821Q 10 4 INTERNATIONAL BRIQUETTES HLDG ORD G4933P 10 1 IPC HLDGS LTD ORD 649398 10 3 * IRIDIUM WORLD COMMUNICATIONS CL A 649398 90 3 IRIDIUM WORLD COMMUNICATIONS CALL 649398 95 3 IRIDIUM WORLD COMMUNICATIONS PUT 649864 10 4 IWI HLDG LTLI ORD G5138L 10 0 JINPAN INTL LTD ORD 652996 10 6 KNIGHTSBRIDGE TANKERS LTD ORD 653839 10 1 LASALLE RE HLDGS LTD ORD 655312 10 5 LJ INTL INC ORD ADDED 655312 11 3 LJ INTL INC WT EXP 041503 ADDED 656462 10 7 * LORAL SPACE 8 COMMUNICATIONS COM 656462 90 7 LORAL SPACE & COMMUNICATIONS CALL 656462'95 7 LORAL SPACE & COMMUNICATIONS PUT 661061 10 0 * MID OCEAN LIMITED ORD CL A 661061 90 0 MID OCEAN LIMITED CALL 661061 95 0 MID OCEAN LIMITED PUT 665773 10 6 NORDIC AMERICAN TANKER SHIPPNG COM 665834 12 3 NORD PAC LTU ORD NEW 66674P 10 9 NOVEL DENIM HLDGS LID ORD G6852T 10 5 PARTNERRE LTD COM 669586 10 8 PEAK INTL LTD ORD G7342H 10 7 * RADICA GAMES LTD ORD G7342H 90 7 RADICA GAMES LTD CALL G7342H 95 7 RADICA GAMES LTD PUT 674966 10 3 RENAISSANCE RE HLDGS LTD COM G7702U 10 2 * RSL COMMUNICATIONS LTD CL A G7702U 90 2 RSL COMMUNICATIONS LTD CALL G7702U 95 2 RSL COMMUNICATIONS LTD PUT G7805C 10 8 * SANTA FE INPL CORP ORD G7805C 90 8 SANTA FE INTL CORP CALL G7805C 95 8 SANTA FE INTL CORP PUT 681226 10 5 SIEM INDS INC COM ADDED 681654 10 8 SINOAMERICAN TELECOM INC ORD 684951 10 5 STXRLING COOKE BROWN HLDGS LTD ORD G87615 10 3 TERRA NOVA BERMUDA HLDGS LTD ORD CL A RUN DATE:06/23/98 ** LIST OF SECTION 13F SECURITIES ** PAGE 3 RUN TIME:16:46 IVMOOl CUSIP NO. ISSUER NAME ISSUER DESCRIPTION STATUS G8846W 10 3 3D LABS INC LTD ORD 689152 10 2 * HILFIGER TOMMY CORP ORD 689152 90 2 HILFIGER TOHMY CORP CALL 689152 95 2 HILFIGEK TOMMY CORP PUT 689935 10 3 TRAMFORD INIL LTD ORD 689935 11 1 TRAMFORD INTL LTD WT EXP 121399 690751 10 1 * TRITON ENERGY LTD ORD 690751 90 1 TRITON ENERGY LTD CALL 690751 95 1 TRITON ENERGY LTD PUT K7514Y 10 7 * OLICOM A/S ORD K7514Y 90 7 OLICOM A/S CALL K7514Y 95 7 OLICOM A/S PUT K7514Y 12 3 OLICOM A/S WT EXP 091200 L20708 10 0 CRONOS GROUP N V ORD L6388F 10 2 * MILLICOM IN1-L CELLULAR S A ORD L6388F 90 2 MILLICOM INPL CELLULAR S A CALL L6388F 95 2 MILLICOM INTL CELLULAR S A PUT L8137H 10 8 SCANDINAVIAN BROADCASTING SYS ORD L8873E 10 3 STOLT COMEX SEAWAY SA COM L88742 10 8 STOLT NIELSEN S A COM M01575 10 5 ACCENT SOFTWARE INTL LTD COM M01575 15 4 ACCENT SOFTWARE INTL LTD UNIT EX 071998 M01770 10 2 ACS ELECTRONICS LTD ORD -M0392N 10 1 ALADDIN KNOWLEDGE SYS LTD ORD Mi4925 10 7 AREL COMMUNlCATIONS & SOFTWARE COM M14925 11 5 AREL COMMUNICATIONS 8 SOFTWARE WT A EX 120198 M14950 10 5 ARIELY ADVEETISING LTD ORD DELETED M15015 10 6 ARZAN INTL (1991) LTD ORD DELETED M15015 11 4 ARZAN INTL (1991) LTD WT EXP 031299 DELETED M20115 10 7 BOS BETTER ONLINE SOLUTIONS ORD M20115 11 5 BOS BETTER ONLINE SOLUTIONS WT EXP 040299 M20514 10 1 BVR TECHNOLOGIES LTD ORD M22465 10 4 * CHECK POINT SOFTWARE TECH LTD ORD M22465 90 4 CHECK POINT SOFTWARE TECH LTD CALL M22465 95 4 CHECK POINT SOFTWARE TECH LTD PUT M23798 10 7 CIMATRON LTU ORD M26763 10 8 CRYSTAL SYS SOLUTIONS LTD ORD M3040Q 10 4 EDUSOFT LTD ORD M3752J 10 8 ELBIT LTD ORD M37576 10 1 ELBIT VISION SYS LTD ORD M3760D 10 1 ELBIT SYS LID ORD M37605 10 8 ELBIT MEDICAL IMAGING LTD ORD M3909Q 10 4 ELECTR0CHEMl:CAL INDS 1952 LTD ORD M40105 11 2 ELRON ELECTRONIC INUS WT EXP 090198 M40168 10 2 ELSCINT LTD NEW ORD M40184 10 9 ELTEK LTD ORD M40515 10 4 ENGEL GENERAL DEVELOPERS LTD ORD M40868 10 7 * ESC MEDICAL SYS LTD ORD M40868 90 7 ESC MEDICAL SYS LTD CALL RUN DATE:06/23/98 ** LIST OF SECTION 13F SECURITIES ** PAGE 4 RUN TIME:16:46 IVMOOl CUSIP NO.
Load more

Recommended publications
  • Download the 54Th Annual Program Book
    THE 54TH ANNUAL DECEMBER 4, 2020 1 Welcome To The We celebrate Fifty-Fourth Annual Cable TV Pioneers and appreciate Induction Celebration everything you are, and all that you do. Class of 2020 Induction Gala Charter Field Operations In Appreciation of C-SPAN would like to congratulate Ann Our Sponsors on joining the esteemed ranks How It All Began Officers and Managing Board of the Cable TV Pioneers The Spirit of the Pioneers who have shaped the Presenting the Class of 2020 Cable TV industry. Congratulations to the 25th Anniversary Class of 1995 In Memorium Active Membership 2020 Celebration Executive Committee David Fellows Yvette Kanouff Patricia Kehoe Michael Pandzik Sean McGrail Your leadership Susan Bitter Smith and forward thinking Jim Faircloth personifi es what it means to be a Cable TV Pioneer. 2 3 We’re Going Special Thanks Primetime Thanks To Our Sponsors To Thank you to our friends at C-SPAN for televising and streaming the induction ceremony for the Class of 2020. C-SPAN was created by the cable industry in 1979 as a gift to the American people and today with their stellar reputation, they are more relevant than ever. Unique to media as a non-profit, C-SPAN is a true public service of the cable and satellite providers that fund it. It’s thanks to the support of so many Cable TV Pioneers that C-SPAN has thrived. Many have served on C-SPAN’s board of directors, while others committed to add the services to their channel line-ups. So many local cable folks have welcomed C-SPAN into their markets to meet with the community and work with educators and local officials.
    [Show full text]
  • Nortel Networks Corp. (Re)
    Page 1 Case Name: Nortel Networks Corp. (Re) RE:IN THE MATTER OF the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended AND IN THE MATTER OF a Plan of Compromise or Arrangement of Nortel Networks Corporation, Nortel Networks Limited, Nortel Networks Global Corporation, Nortel Networks International Corporation and Nortel Networks Technology Corporation, Applicants APPLICATION UNDER the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended [2009] O.J. No. 3169 55 C.B.R. (5th) 229 2009 CarswellOnt 4467 Court File No. 09-CL-7950 Ontario Superior Court of Justice Commercial List G.B. Morawetz J. Heard: June 29, 2009. Judgment: June 29, 2009. Released: July 23, 2009. (59 paras.) Bankruptcy and insolvency law -- Companies' Creditors Arrangement Act (CCAA) matters -- Ap- plication of Act -- Debtor company -- Motion by applicants for approval of bidding procedure and Sale Agreement allowed -- Applicants had been granted CCAA protection and were involved in in- solvency procedures in four other countries -- Bidding procedures set deadline for entry and in- volved auction -- Sale Agreement was for some of applicants' business units -- Neither proposal in- volved formal plan of compromise with creditors or vote, but CCAA was flexible and could be broadly interpreted to ensure objective of preserving business was met -- Proposal was warranted, beneficial and there was no viable alternative. Page 2 Motion by the applicants for the approval of their proposed bidding process and Sale Agreement. The applicants had been granted CCAA protection and were involved in insolvency proceedings in four other countries. The Monitor approved of the proposal.
    [Show full text]
  • The Royal Gazette Index 2010
    The Royal Gazette Gazette royale Fredericton Fredericton New Brunswick Nouveau-Brunswick ISSN 0703-8623 Index 2010 Volume 168 Table of Contents / Table des matières Page Proclamations . 2 Orders in Council / Décrets en conseil . 2 Legislative Assembly / Assemblée législative. 9 Elections NB / Élections Nouveau-Brunswick . 9 Departmental Notices / Avis ministériels . 9 NB Energy and Utilities Board / Commission de l’énergie et des services publics du N.-B. 15 New Brunswick Securities Commission / Commission des valeurs mobilières du Nouveau-Brunswick . 15 Notices Under Various Acts and General Notices / Avis en vertu de diverses lois et avis divers . 15 Sheriff’s Sales / Ventes par exécution forcée . 16 Notices of Sale / Avis de vente . 16 Regulations / Règlements . 19 Corporate Affairs Notices / Avis relatifs aux entreprises . 22 Business Corporations Act / Loi sur les corporations commerciales . 22 Companies Act / Loi sur les compagnies . 58 Partnerships and Business Names Registration Act / Loi sur l’enregistrement des sociétés en nom collectif et des appellations commerciales . 60 Limited Partnership Act / Loi sur les sociétés en commandite . 93 2010 Index Proclamations Right to Information and Protection of Privacy Act / Droit à l’information et la protection de la vie privée, Loi sur le—OIC/DC 2010-381—p. 1656 Acts / Lois (August 18 août) Safer Communities and Neighbourhoods Act / Sécurité des communautés et Civil Forfeiture Act / Confiscation civile, Loi sur la—OIC/DC 2010-314— des voisinages, Loi visant à accroître la—OIC/DC 2010-224—p. 1045 p. 1358 (July 14 juillet) (May 19 mai) Clean Environment Act, An Act to Amend the / Assainissement de Safer Communities and Neighbourhoods Act, An Act to Amend the / Sécurité l’environnement, Loi modifiant la Loi sur l’—OIC/DC 2010-220—p.
    [Show full text]
  • List of Section 13F Securities
    List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder.
    [Show full text]
  • Public Accounts of the Province of Ontario for the Year Ended March
    PUBLIC ACCOUNTS, 1994-95 MINISTRY OF AGRICULTURE, FOOD AND RURAL AFFAIRS Hon. Elmer Buchanan, Minister DETAILS OF EXPENDITURE Voted Salaries and Wages ($87,902,805) Temporary Help Services ($1,329,292): Management Board Secretariat, 1,220,010; Accounts under $50,000—109,282. Less: Recoveries from Other Ministries ($196,635): Environment and Energy, 196,635. Employee Benefits ($13,866,524) Payments for Canada Pension Plan, 1 ,594,486; Dental Plan, 95 1 ,332; Employer Health Tax, 1 ,702,083; Group Life Insurance, 170,970; Long Term Income Protection, 1,028,176; Supplementary Health and Hospital Plan, 1,016,690; Unemployment Insurance, 3,017,224; Unfunded Liability— Public Service Pension Fund, 1,024,574. Other Benefits: Attendance Gratuities, 401,716; Death Benefits, 18,660; Early Retirement Incentive, 467,244; Maternity/Parental/Adoption Leave Allowances, 530,045; Severance Pay, 1,494,057; Miscellaneous Benefits, 51,035. Workers' Compensation Board, 315,097. Payments to Other Ministries ($152,141): Accounts under $50,000—152,141. Less: Recoveries from Other Ministries ($69,006): Accounts under $50,000—69,006. Travelling Expenses ($3,859,979) Hon. Elmer Buchanan, 7,002; P. Klopp, 3,765; R. Burak, 9,912; W.R. Allen, 13,155; D.K. Alles, 16,276; P.M. Angus, 23,969; D. Beattie, 12,681; A. Bierworth, 14,510; J.L. Cushing, 12,125; L.L. Davies, 11,521; P. Dick, 16,999; E.J. Dickson, 11,231; R.C. Donais, 10,703; J.R. Drynan, 10,277; R. Dunlop, 10,662; JJ. Gardner, 43,319; C.L. Goubau, 12,096; N. Harris, 12,593; F.R Hayward, 26,910; M.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Employment Effects of Subsidized Broadband Internet for Low-Income Americans
    Online Appendix: Wired and Hired: Employment Effects of Subsidized Broadband Internet for Low-Income Americans George W. Zuo Appendix A: Appendix Tables and Figures Figure A1: Major Comcast Cable M&A Events: 1990-2018 1994 • Comcast acquires Canadian based Maclean Hunter’s U.S. cable operation based in New Jersey, Michigan, and Florida, adding 550,000 subscribers 1995 • Comcast acquires E.W. Scripps cable systems based in California, Tennessee, Georgia, West Virginia, Florida, and Kentucky, adding 800,000 subscribers 1998 • Comcast acquires Jones Intercable, Inc in the Mid-Atlantic adding 1 million subscribers 1998 • Comcast acquires Prime Communications in Maryland, Virginia, adding 430,000 subscribers 1999 • Comcast acquires Greater Philadelphia Cablevision, Inc in Philadelphia, adding 79,000 subscribers 1999 • Comcast and AT&T enter agreement to exchange cable communications systems, gaining cable communications systems serving 1.5 million subscribers 2000 • Comcast acquires Lenfest Communications in Pennsylvania, Delaware and New Jersey adding 1.3 millions subscribers 2000 • Comcast completes cable swaps with Adelphia and AT&T broadband, gaining customers in Florida, Indiana, Michigan, New Jersey, New Mexico, Pennsylvania and Washington D.C. 2001 • Comcast acquires select AT&T Broadband cable systems in New Mexico, Maryland, Delaware, New Jersey, Pennsylvania and Tennessee adding 585,000 subscribers 2001 • Comcast acquires AT&T Broadband cable systems in Baltimore adding 112,000 subscribers 2001 • Comcast and A&T Broadband merge forming
    [Show full text]
  • Listing of Global Companies with Ongoing Government Activity
    COMPANY LINE OF BUSINESS TICKER A & A BIOTECHNOLOGY S C ADAM BURKIEWICZ MIKOLAJ BURKIEWICZ PHARMACEUTICAL PREPARATIONS A & A GLOBAL INDUSTRIES, INC. AUTOMATIC VENDING MACHINES, NSK A & J ENTERPRISES PHARMACEUTICAL PREPARATIONS A & S INTERNATIONAL 2000 S.R.L. PHARMACEUTICAL PREPARATIONS A & S PHARMACEUTICAL CORP. PHARMACEUTICAL PREPARATIONS A & T MARKETING INC. COMPUTER INTEGRATED SYSTEMS DESIGN, NSK A & T SYSTEMS, INC. TELEPHONE COMMUNICATION, EXCEPT RADIO A & Z PHARMACEUTICAL INC. PHARMACEUTICAL PREPARATIONS A A INTERNATIONAL PHARMACEUTICAL PREPARATIONS A AND V, INC. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC A AROGYA HARBALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A B ENTERPRISES PHARMACEUTICAL PREPARATIONS A B I HERBAL PRODUCTS MEDICINALS AND BOTANICALS, NSK A B S REMEDIES PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A BEAT FOR YOUR FEET, INC. COIN-OPERATED LAUNDRIES AND CLEANING, NSK A BUCKHEAD BUS COMPANY LOCAL PASSENGER TRANSPORTATION, NEC A C C VIEIRA PROTESE ME MEDICINALS AND BOTANICALS, NSK A C CONSULTING PHARMACEUTICAL PREPARATIONS A C E DIAGNOSTICS & BIOTECH LIMITED PHARMACEUTICAL PREPARATIONS A C E PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A C PHARMACEUTICALS PRIVATE LIMITED PHARMACEUTICAL PREPARATIONS A CUT ABOVE LANDSCAPE LAWN AND GARDEN SERVICES A D C O MARKETING INC NONDURABLE GOODS, NEC, NSK A G HERBALS PRIVATE LIMITED MEDICINALS AND BOTANICALS, NSK A G PHARMACEUTICALS PHARMACEUTICAL PREPARATIONS A H C PHARMACAL, INC PHARMACEUTICAL PREPARATIONS A H SYSTEMS INC INSTRUMENTS TO MEASURE ELECTRICITY A HOUSE OF AYURVEDIC
    [Show full text]
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Bioworld Insight
    BioWorld Insight The news source of record covering the development of innovative human therapies October 30, 2017 Actionable Intelligence • Incisive Analysis Volume 25, No. 44 Society needs to urgently address antimicrobial resistance By Peter Winter, Editor The challenge of antimicrobial resistance (AMR) is one we need to urgently solve. In the U.S., the CDC estimates at least 2 million people become infected with bacteria that are resistant to currently available antibiotic therapies annually and approximately 23,000 people will die each year as a direct result of those infections. The threat of AMR has certainly been recognized worldwide and has become a top priority for global policy and public health. See AMR, page 3 Cheaper and faster also testing the drug in combination with immune Oncology drugs checkpoint inhibitors. “You often hear people say inhibiting PD-1 move to China seeking and CCR4 is like reducing the brake on a car. Plinabulin is like adding the fuel,” Huang patients and approvals explained. Nevertheless, she sees opportunities By Brian Orelli, Staff Writer for plinabulin in combination with both With a third of the world’s cancer patients residing chemotherapy and immune checkpoint inhibitors, Inside in China and upward of half of them enrolling in “Chemotherapy isn’t going away; nivolumab only clinical trials, small U.S.-based companies are has a 20 percent response rate.” Money raised by biotech looking across the Pacific to test their oncology On the neutropenia side, last week the company in 2017 drug candidates. enrolled its first patient in China in the global page 4 The advantages of lower cost and increased speed phase II/III trial testing plinabulin as a prevention of chemotherapy-induced neutropenia.
    [Show full text]
  • Lishing Group Group Nature Publishing
    PEOPLE Paul L. Berns (left) has been appointed Allos Therapeutics’ NitroMed (Lexington, MA, USA) has (Westminster, CO, USA) president, CEO and member of the board announced that Argeris (Jerry) Karabelas, of directors. He brings close to 15 years of pharmaceutical industry currently chairman of the board of directors, experience to Allos, holding senior management positions at Abbott has been appointed interim CEO, succeed- Laboratories, BASF Pharmaceuticals and Bristol-Myers Squibb. Mr. ing Michael Loberg, who resigned from his Berns was most recently president, CEO and a member of the board position as president, CEO and director of of directors of Bone Care International. With Mr. Berns’ appointment, NitroMed. In addition, Kenneth Bate, formerly Michael E. Hart has resigned his positions as president, CEO and CFO of Millennium Pharmaceuticals, has been CFO, and David C. Clark, the company’s controller and treasurer, has named chief operating officer and CFO, follow- been appointed to serve as interim CFO until a permanent replacement is found. ing the departure of Lawrence Bloch as CFO and chief business officer. Morphotek (Exton, PA, USA) has announced Privately held NascaCell IP (Munich) has was most recently head of clinical operations the appointment of Robert Radie as chief announced the appointment of cofounder at Vical. business officer and the promotion of Luigi http://www.nature.com/naturebiotechnology Michael Blind to the position of CEO. Dr. Grasso to senior vice president of R&D. Mr. Blind was previously responsible for research VLST Corp. (Seattle, WA, USA) has announced Radie was most recently senior vice president and development activities at NascaCell.
    [Show full text]
  • Cancer Vaccine Therapies: Failures and Future Opportunities Michael D
    Cancer Vaccine Therapies: Failures and Future Opportunities Michael D. Becker, Janet Dally, and Jeffrey Martini, Ph.D. Michael D. Becker President & CEO [email protected] Janet Dally Senior Vice President [email protected] Jeffrey Martini, Ph.D. Vice President [email protected] MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com www.mdbpartners.com Copyright © 2010 MD Becker Partners LLC All rights reserved MD Becker Partners LLC [This page intentionally left blank] Cancer Vaccine Therapies: Failures and Future Opportunities Page 2 MD Becker Partners LLC MD Becker Partners’ reports are limited publications that contain valuable information provided to a select group of customers. Our reports are for our customers’ internal use and not for general publication or disclosure to third parties. No part of this report may be given, lent, resold, or disclosed to non-customers without written permission. Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher. For additional information, please refer to Appendix G: Legal Disclaimer. For information regarding permission, write: MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry, including pharmaceuticals, biotechnology, and medical devices. We also work with venture capitalists, institutional investors, and others that provide capital to these companies.
    [Show full text]